Acronym:
DREAMM7
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Other | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III | Tumour Stream | Multiple myeloma |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Multiple myeloma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A multi-centre, open-label, randomised phase III study to evaluate the efficacy and safety of the combination of GSK2857916, bortezomib, and dexamethasone compared with the combination of daratumumab, bortezomib and dexamethasone in participants with relapsed/ refractory multiple myeloma.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Calvary North Adelaide Hospital | Julie Rowe | julie.rowe@calvarycare.org.au | 08 8239 9536 | Not Yet Recruiting |